<DOC>
	<DOCNO>NCT00612573</DOCNO>
	<brief_summary>Randomized , multi-center , double-blind , placebo-controlled 12-week study ass safety efficacy 3 dose oral formulation Doxycycline oral tablet use Investigator 's Global Assessment ( IGA ) score absolute change baseline inflammatory lesion count patient moderate severe facial acne vulgaris . Additionally , absolute change baseline non-inflammatory total lesion active study medication placebo evaluate .</brief_summary>
	<brief_title>Treatment Moderate Severe Facial Acne Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>Must 12 45 year age . Has diagnosis moderate severe facial acne vulgaris two nodule face Is allergic tetracyclineclass antibiotic ingredient study medication . Has history pseudomembranous colitis antibioticassociated colitis . Has history hepatitis liver damage renal impairment .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>